Validation of a biological candidate drug
| Reference number | |
| Coordinator | LIPUM AB |
| Funding from Vinnova | SEK 990 850 |
| Project duration | June 2018 - November 2019 |
| Status | Completed |
Purpose and goal
Lipum has identified a protein (BSSL) as a unique target molecule for treatment of chronic inflammatory diseases. The biological drug is an antibody that blocks BSSL and thus stops inflammation. Just as intended with the project, we have selected and validated the antibody that has become our drug candidate (SOL-116), that has been evaluated in disease models with positive results. This has led to increased interest from pharma companies and investors. During the project period Lipum received support from Horizon 2020 of € 2.2 million and made a new issue of SEK 25 million.
Expected results and effects
Through the project Lipum has been able to implement and document the choice and optimization of the drug candidate SOL-116. Thus, the company has been able to take a decisive step towards a new drug that is expected to offer an alternative to the chronically ill who are not helped by today´s pharmaceuticals.
Planned approach and implementation
In drug development, almost all scheduling is dynamic, as one must almost expect the unexpected. It is therefore complicated to specify future costs when seeking financial support or investors. However, the starting point must be to assume that everything goes according to plan. Unfortunately, we encountered an unexpected technical problem that disturbed the planning, but after a dialogue with Vinnova this could be solved through extended project time. Thus, we managed to achieve our objective and verify the suitability of our drug candidate SOL-116.